Physician profile
Jay J Libys
NPI 1649380536
$2,493.19
in general payments reported to CMS, 2019-2025
26 companies · $835 in 2025
The $835 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.57 · 2020: $12.85 · 2021: $297 · 2022: $522 · 2023: $311 · 2024: $465 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $779.61 | 2021-2025 | Aveir, Cardiomems, Merlin@Home |
| Novartis Pharmaceuticals Corporation | $352.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $305.34 | 2024-2025 | Camzyos, Eliquis |
| Abiomed | $129.06 | 2022 | |
| Medtronic, INC. | $99.57 | 2021-2025 | Micra |
| Biotronik INC. | $76.97 | 2019-2025 | Acticor 7 Vr-T Dx |
| Novo Nordisk INC | $74.25 | 2021-2023 | Wegovy |
| Edwards Lifesciences Corporation | $67.69 | 2025 | |
| Philips North America LLC | $59.14 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Merck Sharp & Dohme LLC | $56.85 | 2021-2022 | |
| Amgen INC. | $54.05 | 2020-2021 | |
| Baxter Healthcare | $49.03 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $45.00 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $43.68 | 2022 | |
| Heartflow, INC. | $40.30 | 2023 | Ffrct |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.43 | 2022 | |
| Janssen Pharmaceuticals, INC | $31.67 | 2021 | |
| Pfizer INC. | $28.66 | 2023 | |
| Dynavax Technologies Corporation | $26.97 | 2022 | |
| United Therapeutics Corporation | $25.58 | 2024 | |
| Lundbeck LLC | $22.71 | 2019 | |
| Lilly USA, LLC | $22.25 | 2022 | |
| Impulse Dynamics (USA) INC. | $20.65 | 2022 | |
| Silk Road Medical, INC. | $20.57 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $14.52 | 2021 | |
| Mylan Specialty L.P. | $14.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Libys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.